Myocardial Infarction News and Research

RSS

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

Schering-Plough Corporation today announced the start of patient enrollment in RED-CABG, the Phase 3 Trial for acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA). Acadesine was licensed from PeriCor Therapeutics, Inc., a privately held specialty biopharmaceutical company.

12 May 2009

FDA approves Avastin (bevacizumab) for treatment of glioblastoma multiforme

The U.S. Food and Drug Administration recently approved Avastin (bevacizumab) to treat patients with glioblastoma multiforme (GBM) when this form of brain cancer continues to progress following standard therapy.

7 May 2009

Low blood pressure may increase risk of heart attack and stroke

Data from the Treating to New Targets (TNT) trial presented today at the American Society of Hypertension's Twenty Fourth Annual Scientific Meeting (ASH 2009) show that low blood pressure levels may lead to increased risk of cardiovascular events, including heart attack and stroke. These data supplement previous findings from the TNT trial of atorvastatin showing aggressive LDL cholesterol-lowering reduced cardiovascular events.

7 May 2009

Studies indicate why females do not fare as well as men in undergoing angioplasty for heart attacks

Age, condition and treatment delay are among the reasons women who undergo angioplasty for heart attack often do not fare as well as do men, according to two studies presented today at the Society for Cardiovascular Angiography and Interventions (SCAI) 32nd Annual Scientific Sessions.

6 May 2009

Results from study comparing safety and efficacy of drug-eluting stents and bare-metal stents

The Cardiovascular Research Foundation (CRF) announced that its landmark study comparing the safety and efficacy of drug-eluting stents and bare-metal stents was published today in The New England Journal of Medicine.

6 May 2009

Autoantibodies may be created in response to bacterial DNA

Autoimmune diseases have long been regarded as illnesses in which the immune system creates autoantibodies to attack the body itself. But today, researchers at the California non-profit Autoimmunity Research Foundation (ARF) explain that the antibodies observed in autoimmune disease actually result from alteration of human genes and gene products by hidden bacteria.

27 Apr 2009

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

In order to better prevent blood clots, clopidogrel can be prescribed to patients with acute ischaemia of the heart muscle, in addition to acetylsalicylic acid (ASA).

22 Apr 2009

Telemonitoring changes the working practice of cardiac nurses

The 9th Annual Spring Meeting of the European Society of Cardiology Council on Cardiovascular Nursing and Allied Professions (CCNAP), organised in cooperation with the Irish Nurses Cardiovascular Association (INCA), is being held at the Royal Dublin Society, Dublin, Ireland, on 24-25 April.

8 Apr 2009

Moderate kidney disease associated with cardiovascular events

Chronic kidney disease patients face a greater risk of cardiovascular events such as stent thrombosis after being treated for heart attacks, even if their kidney disease is moderate, according to researchers from Wake Forest University Baptist Medical Center.

6 Apr 2009

Accurate assessment of heart disease leads to earlier, more aggressive therapy

In a study comparing the ability of various medical techniques to accurately determine the extent of heart disease and stratify patients according to disease severity, researchers found that myocardial perfusion testing with gated single photon emission computed tomography (gated SPECT) was a more accurate predictor of prognosis in chronic ischemic heart disease (IHD)-a painful condition caused by a temporary reduction of oxygen-rich blood to the heart.

1 Apr 2009

World Heart Federation, Daiichi Sankyo and Lilly Partner to improve cardiovascular health

The World Heart Federation, Daiichi Sankyo Company, and Eli Lilly announced today that they have partnered to improve cardiovascular health internationally. The organizations made the announcement at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, Florida.

31 Mar 2009

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

Nile Therapeutics, Inc. has announced that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile submitted to the U.S. Food and Drug Administration (FDA) to support the initiation of the Company's Phase IIb clinical trial with CD-NP for the treatment of acute heart failure, the FDA has placed CD-NP on clinical hold.

30 Mar 2009

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Lantheus Medical Imaging, Inc has announced new data regarding the use of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension.

29 Mar 2009

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

ARCA biopharma, Inc. has announced that data from the pivotal Phase 3 BEST trial of Gencaro (bucindolol hydrochloride) in patients with advanced chronic heart failure (CHF) was presented at the American College of Cardiology 58 th Annual Scientific Session being held March 29-31, 2009 in Orlando, Florida.

29 Mar 2009

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

Results from a new sub-analysis of the JUPITER study show that patients who attained a dual treatment target of LDL-C <70mg/dL and high-sensitivity C-reactive protein (hsCRP) <2mg/L with CRESTOR (rosuvastatin) 20mg achieved a greater reduction in cardiovascular events compared to placebo than those who did not (65% vs 36%, p=0.033) among men and women with low to normal cholesterol levels and elevated hsCRP.

29 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.

29 Mar 2009

Transdermal delivery of estrogen therapy may show safety benefits as opposed to oral delivery

Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests.

29 Mar 2009

New target for heart failure therapy identified

A novel signaling pathway plays a significant role in the production of aldosterone, a hormone that promotes heart failure after a myocardial infarction, according to a study conducted by Thomas Jefferson University researchers.

16 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Myocardial Infarction News and Research

Schering-Plough starts patient enrollment in phase 3 trial for Acadesine

FDA approves Avastin (bevacizumab) for treatment of glioblastoma multiforme

Low blood pressure may increase risk of heart attack and stroke

Studies indicate why females do not fare as well as men in undergoing angioplasty for heart attacks

Results from study comparing safety and efficacy of drug-eluting stents and bare-metal stents

Autoantibodies may be created in response to bacterial DNA

Acetylsalicylic acid plus clopidogrel reduces heart attack risk in patients with acute ischaemia

Telemonitoring changes the working practice of cardiac nurses

Moderate kidney disease associated with cardiovascular events

Accurate assessment of heart disease leads to earlier, more aggressive therapy

World Heart Federation, Daiichi Sankyo and Lilly Partner to improve cardiovascular health

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

ARCA biopharma presents data from phase 3 BEST trial of Gencaro

CRESTOR found to reduced CV risk in patients achieving low LDL-C and hsCRP targets in new Jupiter analysis

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Transdermal delivery of estrogen therapy may show safety benefits as opposed to oral delivery

New target for heart failure therapy identified

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News